drugset / Trial / NCT02365233
Fatty Liver Study in Patients With Type II Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Timeline
- Start
- 2013-05-01
- Primary completion
- 2016-12-31
- Completion
- 2016-12-31
Outcome
Outcome not reported
Stopped: “IRB withheld the data due to inadequate supporting documentation”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LANTUS insulin | Protein / enzyme biologic | 0.35 iu/kg | — |
| Comparator | Pioglitazone | Small molecule | 15 mg | — |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |